Previous 10 | Next 10 |
Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company’s manufacturing facility and presentation of favorable preclinical data Closed venture debt financing with Silicon Valley Bank, strengthening balance sheet and e xten...
ACM, AMC, APPS, ATCO, CABO, CBT, CCXI, CF, CHGG, CMBM, CMP, COMP, CXW, DDD, DHT, DOOR, ELY, ESE, ETH, EVBG, FGEN, FLGT, HALO, HBM, HLIO, INO ,IPAR, MESA, MODN, NCMI, NHI, NTR, OSH, PEN, PLNT, PRPL, QLYS, RCKT, REAL, RETA, RGNX, RPAY, SAIL, SDC, STE, TPTX, VUZI, WES, ZIOP For Seeking Alpha's f...
BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2...
Ziopharm Oncology, Inc. is a non-revenue-producing early clinical-stage biopharmaceutical company aiming to develop or acquire immuno-oncology therapies. Ziopharm's current product candidates include TCR+T therapies targeting solid tumors, CAR-T therapies targeting CD19 for hemat...
courtneyk/E+ via Getty Images After bottoming out in mid-May, the NASDAQ Biotechnology Index is on track to reach its highest level since late February as heavily shorted stocks are rallying today. On Monday, the market-cap weighted index rose ~3.4% recording its biggest one-day gain since No...
Gainers: Aethlon Medical AEMD +425%, Checkpoint Therapeutics CKPT +26%, Adamis Pharmaceuticals ADMP +12%, SCWorx (WORX) +18%, ZIOPHARM Oncology ZIOP +15%.Losers: Atossa Therapeutics ATOS -14%, CEL-SCI CVM -11%, Precipio (PR...
ZIOPHARM Oncology ([[ZIOP]] +15.2%) has ended the three-day losing streak recording what could be its highest one-day gain in nearly four months if the momentum continues.The clinical-stage biopharma company has more than a fifth of its shares on loan and with a loss of ~9.9% over the past 12...
– Highlighted distinctive cellular therapy program, market opportunity and value proposition – Shared optimistic outlook and commitment to deliver value to shareholders – Encouraged by overwhelming vote of shareholders in favor of the Company...
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Ziopharm Oncology Inc (NASDAQ: ZIOP) Q1 2021 Earnings Call May 6, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Ziopharm Oncology Inc (ZIOP) Q1 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...